WO2013090986A1 - Treatment of seborrhoea - Google Patents

Treatment of seborrhoea Download PDF

Info

Publication number
WO2013090986A1
WO2013090986A1 PCT/AU2012/001543 AU2012001543W WO2013090986A1 WO 2013090986 A1 WO2013090986 A1 WO 2013090986A1 AU 2012001543 W AU2012001543 W AU 2012001543W WO 2013090986 A1 WO2013090986 A1 WO 2013090986A1
Authority
WO
WIPO (PCT)
Prior art keywords
scymnol
ester
treatment
pharmaceutically acceptable
seborrhoea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU2012/001543
Other languages
English (en)
French (fr)
Inventor
Theodore Macrides
Andrew Broadbent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MCFARLANE MARKETING (AUST) Pty Ltd
Original Assignee
MCFARLANE MARKETING (AUST) Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011905331A external-priority patent/AU2011905331A0/en
Priority to CA2859826A priority Critical patent/CA2859826A1/en
Priority to SG11201403078RA priority patent/SG11201403078RA/en
Priority to KR1020147020089A priority patent/KR20140120890A/ko
Priority to EP12859788.7A priority patent/EP2793897B1/en
Priority to NZ625852A priority patent/NZ625852B2/en
Priority to JP2014547630A priority patent/JP2015500841A/ja
Priority to HK15100268.8A priority patent/HK1199818B/en
Priority to DK12859788.7T priority patent/DK2793897T3/en
Priority to RU2014126635A priority patent/RU2624238C2/ru
Priority to BR112014014968A priority patent/BR112014014968A2/pt
Priority to ES12859788.7T priority patent/ES2632591T3/es
Priority to IN4693CHN2014 priority patent/IN2014CN04693A/en
Application filed by MCFARLANE MARKETING (AUST) Pty Ltd filed Critical MCFARLANE MARKETING (AUST) Pty Ltd
Priority to MX2014007659A priority patent/MX2014007659A/es
Priority to AU2012321108A priority patent/AU2012321108B2/en
Priority to CN201280063798.3A priority patent/CN104144689A/zh
Priority to US14/366,261 priority patent/US20140364405A1/en
Priority to PL12859788T priority patent/PL2793897T3/pl
Publication of WO2013090986A1 publication Critical patent/WO2013090986A1/en
Priority to ZA2014/04348A priority patent/ZA201404348B/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin

Definitions

  • the present invention also extends to a composition for use in the treatment of seborrhoea in a patient, which comprises an effective amount of (24RS) or (24S) scymnol, an ester thereof or a pharmaceutically acceptable salt of a said ester, or of (24R) scymnol, together with a pharmaceutically acceptable carrier or diluent.
  • Enzymes and receptors in cells commonly select for one enantiomer of a chiral binding molecule (substrate or ligand) over the other enantiomer, because of the chirally- selective pockets inside their active sites. This is why most natural biological molecules (e.g. amino acids and sugars) are present in cells in only one chiral form.
  • beneficial bioactivity from the overall dose (if it is inactive compared to the beneficial enantiomer), or even less than half of the beneficial bioactivity (if it antagonises the beneficial enantiomer), or unwanted and/or adverse side effects (if it has a different bioactivity and/or toxicity profile to the beneficial enantiomer).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
PCT/AU2012/001543 2011-12-20 2012-12-14 Treatment of seborrhoea Ceased WO2013090986A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
PL12859788T PL2793897T3 (pl) 2011-12-20 2012-12-14 Leczenie łojotoku
ES12859788.7T ES2632591T3 (es) 2011-12-20 2012-12-14 Tratamiento de la seborrea
KR1020147020089A KR20140120890A (ko) 2011-12-20 2012-12-14 지루의 치료
EP12859788.7A EP2793897B1 (en) 2011-12-20 2012-12-14 Treatment of seborrhoea
NZ625852A NZ625852B2 (en) 2011-12-20 2012-12-14 Treatment of seborrhoea
JP2014547630A JP2015500841A (ja) 2011-12-20 2012-12-14 脂漏症の治療
HK15100268.8A HK1199818B (en) 2011-12-20 2012-12-14 Treatment of seborrhoea
DK12859788.7T DK2793897T3 (en) 2011-12-20 2012-12-14 TREATMENT OF SEBORIE
RU2014126635A RU2624238C2 (ru) 2011-12-20 2012-12-14 Лечение себореи
CA2859826A CA2859826A1 (en) 2011-12-20 2012-12-14 Treatment of seborrhoea
IN4693CHN2014 IN2014CN04693A (enExample) 2011-12-20 2012-12-14
SG11201403078RA SG11201403078RA (en) 2011-12-20 2012-12-14 Treatment of seborrhoea
BR112014014968A BR112014014968A2 (pt) 2011-12-20 2012-12-14 tratamento contra seborréia
MX2014007659A MX2014007659A (es) 2011-12-20 2012-12-14 Tratamiento de seborrea.
AU2012321108A AU2012321108B2 (en) 2011-12-20 2012-12-14 Treatment of seborrhoea
CN201280063798.3A CN104144689A (zh) 2011-12-20 2012-12-14 皮脂溢的治疗
US14/366,261 US20140364405A1 (en) 2011-12-20 2012-12-14 Treatment of seborrhoea
ZA2014/04348A ZA201404348B (en) 2011-12-20 2014-06-12 Treatment of seborrhoea

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2011905331 2011-12-20
AU2011905331A AU2011905331A0 (en) 2011-12-20 Treatment of seborrhoea
AU2012900670A AU2012900670A0 (en) 2012-02-22 Treatment of seborrhoea
AU2012900670 2012-02-22

Publications (1)

Publication Number Publication Date
WO2013090986A1 true WO2013090986A1 (en) 2013-06-27

Family

ID=48667492

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2012/001543 Ceased WO2013090986A1 (en) 2011-12-20 2012-12-14 Treatment of seborrhoea

Country Status (20)

Country Link
US (1) US20140364405A1 (enExample)
EP (1) EP2793897B1 (enExample)
JP (1) JP2015500841A (enExample)
KR (1) KR20140120890A (enExample)
CN (1) CN104144689A (enExample)
AU (1) AU2012321108B2 (enExample)
BR (1) BR112014014968A2 (enExample)
CA (1) CA2859826A1 (enExample)
DK (1) DK2793897T3 (enExample)
ES (1) ES2632591T3 (enExample)
HU (1) HUE033800T2 (enExample)
IN (1) IN2014CN04693A (enExample)
MX (1) MX2014007659A (enExample)
MY (1) MY165030A (enExample)
PL (1) PL2793897T3 (enExample)
PT (1) PT2793897T (enExample)
RU (1) RU2624238C2 (enExample)
SG (1) SG11201403078RA (enExample)
WO (1) WO2013090986A1 (enExample)
ZA (1) ZA201404348B (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026883A (en) * 1986-08-21 1991-06-25 Yoshiki Kosuge Derivatives of scymol sulfate
WO1995010283A1 (en) * 1993-10-12 1995-04-20 J.W. Broadbent Nominees Pty. Ltd. Treatment of medical disorders associated with free radical formation
JP2007063139A (ja) * 2005-08-29 2007-03-15 Daicho Kikaku:Kk 皮膚用剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007244325A (ja) * 2006-03-17 2007-09-27 Daicho Kikaku:Kk 新しい健康食品

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026883A (en) * 1986-08-21 1991-06-25 Yoshiki Kosuge Derivatives of scymol sulfate
WO1995010283A1 (en) * 1993-10-12 1995-04-20 J.W. Broadbent Nominees Pty. Ltd. Treatment of medical disorders associated with free radical formation
JP2007063139A (ja) * 2005-08-29 2007-03-15 Daicho Kikaku:Kk 皮膚用剤

Also Published As

Publication number Publication date
ES2632591T3 (es) 2017-09-14
MY165030A (en) 2018-02-28
CA2859826A1 (en) 2013-06-27
HK1199818A1 (en) 2015-07-24
HUE033800T2 (en) 2018-01-29
JP2015500841A (ja) 2015-01-08
KR20140120890A (ko) 2014-10-14
EP2793897B1 (en) 2017-04-12
RU2014126635A (ru) 2016-02-10
DK2793897T3 (en) 2017-07-31
PL2793897T3 (pl) 2017-10-31
AU2012321108A1 (en) 2013-07-04
AU2012321108B2 (en) 2015-07-09
NZ625852A (en) 2015-07-31
EP2793897A1 (en) 2014-10-29
CN104144689A (zh) 2014-11-12
BR112014014968A2 (pt) 2017-06-13
MX2014007659A (es) 2014-11-14
SG11201403078RA (en) 2014-07-30
ZA201404348B (en) 2016-10-26
RU2624238C2 (ru) 2017-07-03
EP2793897A4 (en) 2015-04-08
PT2793897T (pt) 2017-07-17
US20140364405A1 (en) 2014-12-11
IN2014CN04693A (enExample) 2015-09-18

Similar Documents

Publication Publication Date Title
EP2498772B1 (en) Composition and methods for improving skin appearance
KR101514970B1 (ko) 피토스핑고신-1-포스페이트 또는 그 유도체를 포함하는 아토피 또는 피부상처 치료 또는 예방용 조성물
WO1999059580A1 (en) Preventives/remedies for skin diseases
US20050137164A1 (en) Diclofenac compositions for the treatment of skin disorders
JP6725207B2 (ja) 皮膚色素沈着抑制剤
MX2014012704A (es) Composicion farmaceutica topica, proceso de produccion de la composicion farmaceutica topica, uso de la composicion farmaceutica topica y metodo de tratamiento topico de psoriasis, dermatitis atopica o eczemas cronicos.
AU2012321108B2 (en) Treatment of seborrhoea
JP7001356B2 (ja) 皮膚色素沈着抑制剤
HK1199818B (en) Treatment of seborrhoea
JP2014114234A (ja) 皮膚外用剤
KR101733189B1 (ko) 손톱 또는 발톱 성장 촉진용 조성물
NZ625852B2 (en) Treatment of seborrhoea
JP5746807B2 (ja) 皮膚用化粧品の組成物
KR20130077953A (ko) 카르노스산 또는 그 유도체를 함유하는 엘라스테이즈 활성 저해제
JPH10245393A (ja) トリテルペン類を含有する組成物
EA039464B1 (ru) Композиции для местного применения для ухода за кожей
JPH10245394A (ja) 新規なトリテルペン類およびこれを含有する組成物
KR20240167400A (ko) 염증성 피부 질환의 예방 또는 치료용 조성물
JP2000169497A (ja) 新規なトリテルペン類およびこれを含有する組成物
KR20040065864A (ko) 피부알러지 완화 및 예방용 조성물
KR102084521B1 (ko) 여드름 예방 및 개선용 조성물
JP2009155222A (ja) ニキビ改善剤およびニキビ改善用皮膚外用剤
WO2021189077A1 (en) Methods for treating acne
JPH11246413A (ja) ステロイド５α−レダクターゼＩＩ型特異的阻害剤
JPH11246414A (ja) ステロイド５α−レダクターゼＩＩ型特異的阻害剤

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2012321108

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12859788

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 14366261

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2014547630

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2859826

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2012859788

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012859788

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/007659

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 20147020089

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2014126635

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014014968

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014014968

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140618